NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, News, & Analysis

$310.83
+4.20 (+1.37 %)
(As of 06/20/2019 08:00 AM ET)
Today's Range
$303.77
Now: $310.83
$311.90
50-Day Range
$297.44
MA: $312.04
$343.14
52-Week Range
$295.27
Now: $310.83
$442.00
Volume969,453 shs
Average Volume708,364 shs
Market Capitalization$33.97 billion
P/E Ratio15.70
Dividend YieldN/A
Beta1.13
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.71 billion
Cash Flow$22.5076 per share
Book Value$80.34 per share

Profitability

Net Income$2.44 billion

Miscellaneous

Employees7,400
Market Cap$33.97 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its earnings results on Tuesday, May, 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing analysts' consensus estimates of $5.24 by $0.79. The biopharmaceutical company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The company's revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $4.67 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Regeneron Pharmaceuticals.

What price target have analysts set for REGN?

19 equities research analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $305.00 to $480.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $391.2941 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.

What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Regeneron’s fourth-quarter results were impressive as the company comfortably beat on both the top and the bottom line. Regeneron’s growth driver, Eylea continues to drive sales, and label expansion of the drug into additional indications has further boosted growth. Dupixent too has boosted performance. The company is working to expand Dupixent’s label further in several other indications. This should diversify the company’s revenue base and reduce dependence on Eylea. In September 2018, the FDA approved its immuno-oncology therapy, Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. New drug approvals boost growth prospects of the company. Shares have outperformed the industry in the past six months. However, the company is highly dependent on Eylea for growth." (2/8/2019)
  • 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral." (11/7/2018)

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Media headlines about REGN stock have trended neutral on Thursday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Regeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totalling 2,514,900 shares, a decline of 5.2% from the April 15th total of 2,654,000 shares. Based on an average daily trading volume, of 824,000 shares, the short-interest ratio is presently 3.1 days. Approximately 3.2% of the company's stock are short sold. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Celgene (CELG), Gilead Sciences (GILD), Biogen (biib), Alibaba Group (BABA), NVIDIA (NVDA), Tesla (TSLA), Amgen (AMGN), Allergan (AGN) and Alphabet (GOOG).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.53%), FMR LLC (4.05%), American Century Companies Inc. (0.95%), Northern Trust Corp (0.89%), Sustainable Growth Advisers LP (0.84%) and Pictet Asset Management Ltd. (0.45%). Company insiders that own Regeneron Pharmaceuticals stock include Charles A Baker, Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Clearbridge Investments LLC, Janus Henderson Group PLC, Los Angeles Capital Management & Equity Research Inc., Manning & Napier Group LLC, State of Tennessee Treasury Department, Nippon Life Global Investors Americas Inc. and Acadian Asset Management LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Nomura Asset Management Co. Ltd., BlackRock Inc., Hexavest Inc., MERIAN GLOBAL INVESTORS UK Ltd, First Trust Advisors LP, Pictet Asset Management Ltd. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $310.83.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $33.97 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,249 (Vote Outperform)
Underperform Votes:  1,040 (Vote Underperform)
Total Votes:  2,289
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel